SRSF2 and breast carcinoma: The elevated ratio of CDC25C C5/C1 detected in our TF-1 SRSF2-P95 mutants, has also been reported to be induced in breast cancer cells by treatment with sublethal doses of DNA-damaging agents, such as cisplatin (CIS) and doxorubicin [31].